Alonate-P 400 mg/g Oral Paste for Horses and Ponies

Pays: Royaume-Uni

Langue: anglais

Source: VMD (Veterinary Medicines Directorate)

Ingrédients actifs:

Pyrantel Embonate

Disponible depuis:

Cross Vetpharm Group Ltd

Code ATC:

QP52AF02

DCI (Dénomination commune internationale):

Pyrantel Embonate

forme pharmaceutique:

Oral paste

Type d'ordonnance:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

Groupe thérapeutique:

Horses

Domaine thérapeutique:

Anthelmintic

Statut de autorisation:

Authorized

Date de l'autorisation:

2015-03-27

Résumé des caractéristiques du produit

AN: 00498/2014
Issued: March 2015
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF VETERINARY MEDICINAL PRODUCT
Alonate-P 400 mg/g Oral Paste for Horses and Ponies
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Substance
mg/g
Pyrantel embonate
400 mg/g
Excipients
Butylated Hydroxytoluene
0.2 mg/g
For full list of excipients, please see section 6.1.
3.
PHARMACEUTICAL FORM
Oral Paste
Pale yellow to buff coloured paste
4.
CLINICAL PARTICULARS
4.2
TARGET SPECIES
Horses and ponies.
4.3
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Pyrantel embonate is a broad spectrum anthelmintic. Pyrantel embonate
is
indicated for use in the horse for the control and treatment of adult
infections
of large and small strongyles, Pinworms, Roundworms, Tapeworms.
Pyrantel embonate has a broad spectrum of activity, including activity
against:
Large strongyles:
_Stronglylus vulgaris, S. edentatus, S. equinus._
Small strongyles:
_Trichonema spp. (Cyathostomes), Triodontophorus spp._
Pinworms:
_Oxyuris equi, Probstmayria vivipara._
Large roundworms:
_Parascaris equorum._
Tape worms:
_Anoplocephala perfoliata._
4.4
CONTRA-INDICATIONS
Not for use in foals less than 4 weeks of age.
Contraindicated in known sensitivity to pyrantel and in severely
debilitated
animals.
Page 1 of 6
AN: 00498/2014
Issued: March 2015
4.5
SPECIAL WARNINGS FOR EACH TARGET SPECIES.
Care should be taken to avoid the following practices because they
increase
the risk of development of resistance and could ultimately result in
ineffective
therapy:

Too frequent and repeated use of anthelmintics from the same class,
over an extended period of time.

Underdosing, which may be due to underestimation of weight,
misadministration of the product, or lack of calibration of the dosing
device(if any).
Suspected clinical cases of resistance to anthelmintics should be
further
investigated using appropriate tests (e.g. Faecal Egg Count Reduction
Test).
Where the results of the test(s) strongly suggest resistance to a
particular
anthelmintic, an anthelmintic belonging to a